Business Wire03.28.19
Safe Medical Design Inc. (SMD), a medical device company dedicated to developing safe and cost-effective solutions in urology,has received U.S. Food and Drug Administration (FDA) clearance for the Signal Catheter.
A urinary catheter is a flexible tube passed through the urethra and into the bladder to drain urine. Each year in the United States there are as many as 500,000 interventions due to trauma from catheter placement.1 SMD’s SignalCatheter features a novel design and has the potential to reduce urethral trauma as a result of premature balloon inflation during placement.
“This is a monumental shift in a field that has changed very little for the better part of 25 years, despite the over 20 million catheter placements annually in the United States alone,” said CEO Dr. David Aaronson, M.D. “Our device, the Signal Catheter, has the potential to protect patients from unnecessary pain and other complications, while also addressing an issue that costs hospitals $184 million annually.”
Thirty million urethral catheters are placed annually in the United States.2 While over 200,000 incidences of urethral trauma during catheter insertion were officially reported in 2012,3 catheter complications are often underreported with some publications estimating there are closer to 500,000 incidences.
“The accidental inflation of a traditional catheter in the urethra can cause painful, long-lasting and costly damage to patients,” said Dr. Maurice Garcia, Safe Medical Design Inc. founder and Cedars-Sinai Medical Center urologist. “The data we presented at the 2018 American Urological Association (AUA) annual meeting demonstrates that accidental inflation of the catheter’s balloon within the urethra using SMD’s Signal Catheter results in significantly lower intraurethral balloon pressures when compared to the market leading urethral catheter.”
SMD began distribution as part of its early access program in February.
SMD was founded by a team of urologists and engineers in 2012. Funded in part by the National Institute of Health and private financing, SMD is focused on addressing complications in the urology market while reducing overall healthcare costs.
1 Leuck AM, Wright D, Ellingson L, Kraemer L, Kuskowski MA, Johnson JR. Complications of Foley catheters--is infection the greatest risk? J Urol2012 May;187(5):1662-6.
2 ElderM.UScathetermarket.In: GlobalMarkets for Catheters. Wellesley, MA: BCC Research; 2016:91-96
3 The Agency for Healthcare Research on Quality, Healthcare Cost and Utilization Project data, http://hcupnet.ahrq.gov/
A urinary catheter is a flexible tube passed through the urethra and into the bladder to drain urine. Each year in the United States there are as many as 500,000 interventions due to trauma from catheter placement.1 SMD’s SignalCatheter features a novel design and has the potential to reduce urethral trauma as a result of premature balloon inflation during placement.
“This is a monumental shift in a field that has changed very little for the better part of 25 years, despite the over 20 million catheter placements annually in the United States alone,” said CEO Dr. David Aaronson, M.D. “Our device, the Signal Catheter, has the potential to protect patients from unnecessary pain and other complications, while also addressing an issue that costs hospitals $184 million annually.”
Thirty million urethral catheters are placed annually in the United States.2 While over 200,000 incidences of urethral trauma during catheter insertion were officially reported in 2012,3 catheter complications are often underreported with some publications estimating there are closer to 500,000 incidences.
“The accidental inflation of a traditional catheter in the urethra can cause painful, long-lasting and costly damage to patients,” said Dr. Maurice Garcia, Safe Medical Design Inc. founder and Cedars-Sinai Medical Center urologist. “The data we presented at the 2018 American Urological Association (AUA) annual meeting demonstrates that accidental inflation of the catheter’s balloon within the urethra using SMD’s Signal Catheter results in significantly lower intraurethral balloon pressures when compared to the market leading urethral catheter.”
SMD began distribution as part of its early access program in February.
SMD was founded by a team of urologists and engineers in 2012. Funded in part by the National Institute of Health and private financing, SMD is focused on addressing complications in the urology market while reducing overall healthcare costs.
1 Leuck AM, Wright D, Ellingson L, Kraemer L, Kuskowski MA, Johnson JR. Complications of Foley catheters--is infection the greatest risk? J Urol2012 May;187(5):1662-6.
2 ElderM.UScathetermarket.In: GlobalMarkets for Catheters. Wellesley, MA: BCC Research; 2016:91-96
3 The Agency for Healthcare Research on Quality, Healthcare Cost and Utilization Project data, http://hcupnet.ahrq.gov/